Atopic dermatitis: with abrocitinib in patients with lesions and minor pruritus resulting from biologic therapy

A number of major effects on moderate to severe atopic dermatitis treatment with abrocitinib 100 mg provided a stringent response consisting of near complete/complete skin clearance and the risk of pruritus response in patients on dupilumab or placebo.

Results of post hoc analysis of the phase III trial COMPARE JADE presented at the 2024 congress of the European Academy of Dermatology and Venereology (EADV) ensures that the drug can provide a complete and robust response to this patient population.

There atopic dermatitis It is a chronic inflammatory skin condition that manifests itself by recurrent eczematous lesions and intense itching. Patients are affected by the most severe form of the disease which does not respond to topical treatment and can receive a therapeutic system, with dupilumab subcutaneously at a dose of 300 mg every 2 times with abrocitinib, a selective inhibitor of Janus chinasi 1 (JAK1) orally at any dose giornaliera di 100 or 200 mg.

In the Phase III JADE DARE studio, patients work with abrocitinib 200 mg in addition to the subject treatment showed an earlier effect of response from 2 weeks and a response advantage to dupilumab on the very strict end point, certainly with an improvement of the order of 90/100% of the response to basal in the eczema area. and severity index (EASI 90/100) which is maintained until the end of the studio at the beginning of year 26.

In a post hoc analysis of the studio, a significant percentage of patients treated with abrocitinib 200 mg achieved a combined response scored by EASI 90 and a point of 0 to 1 (essence or near pruritus) on the d scale. Numerical assessment of peak pruritus (PP-NRS) rispetto a dupilumab from start 2 of month 26.

More stringent negligible endpoint abrocitinib 100 mg superior to dupilumab and placebo
The post hoc analysis presented at the conference evaluated the effectiveness of abrocitinib at the usual dose of 100 mg compared to dupilumab 300 mg once weekly (after a carico dose of 600 mg) for placebo in the setting of the strict JADE COMPARE endpoint test.

I analyzed data for 238, 242, and 131 patients treated in response to abrocitinib 100 mg, dupilumab, and placebo. Since the start of month 2, a major percentage of participants chose the composite endpoint EASI 90 + PP-NRS 0/1 after treatment with abrocitinib 100 mg, dupilumab and placebo, and continued to increase until ‘at the end of the studio during month 16 (20.2% against 15.5% and 5.4%).

The results from October 16 of the data set showed a higher percentage of patients who took the very stringent EASI 100 response (complete resolution of disease severity) and a point of 0/1 (shovel freed or almost freed from the lesions). ) in the Investigator’s Global Assessment (IGA) after treatment with abrocitinib 100 mg, combined with dupilumab or placebo.

The EASI 100 response is between 12.7%, 5.2% and 4.0% of patients under response to abrocitinib 100 mg, dupilumab and placebo, and at the IGA point from 0 to 12.6%, 6.5% and 4.8% of soggetti.

In a separate analysis, data from patients who did not respond to dupilumab in JADE COMPARE were successively evaluated in the JADE EXTEND studio and were randomized to receive abrocitinib 100 mg. A percentage of support for patients who could not use the end point composed of EASI 90 + assence of pruritus with dupilumab during the settimana in JADE COMPARE gave this rigorous obiettivo with the treatment with abrocitinib 100 mg for 92 settimane in JADE EXTEND

In conclusion, I responded to the report Stéphane Weidinger from the Schleswig-Holstein University Hospital in Kiel, Germany:

• Patients treated with abrocitinib 100 mg were able to achieve a robust response consisting of near complete/complete skin clearance and a pruritus-free state, responding more quickly to this treatment with dupilumab or placebo.
• Treatment with abrocitinib 100 mg resulted in a major percentage of patients reaching the composite endpoint of response to dupilumab or placebo with severe basal pruritus.
• Percentage of patients who, as a priority, did not have an EASI 90 response, plus a pruritus relief state with dupilumab were able to achieve this result after treatment with abrocitinib 100 mg
• Treatment with abrocitinib 100 mg can provide a robust response, from the start of treatment, for patients with moderate to severe atopic dermatitis.

Reference

Weidinger S et al. Stringent efficacy response of skin clearance and itch-free status with abrocitinib 100 mg versus dupilumab in patients with moderate to severe atopic dermatitis: a post-hoc analysis of JADE COMPARE. Presented at the 33rd Annual Congress of the European Academy of Dermatology and Venereology (EADV); Amsterdam, Netherlands; From September 25 to 28, 2024.

Correlatives